Efficacy and Safety of the Vebreltinib in Patients with Previously Treated, Secondary Glioblastoma/idh Mutant Glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A Randomised, Multicentre, Open-Label, Phase II/III Trial.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined